A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hpv 16+ Confirmed Cancers
    Head And Neck Squamous Cell Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Have cancer that has come back or spread to other parts of the body caused by the HPV 16 virus
    2. Have finished receiving radiation therapy to treat their cancer at least 4 weeks before starting the study treatment
    3. Provide tumor tissue samples for analysis which can be either archival tissue (preferably, 2-year-old or more recent but not older than 5 years) or fresh biopsy specimens obtained during the screening process

You may not be eligible for this study if the following are true:

    1. Metastatic central nervous system (CNS) disease and/or carcinomatous meningitis
    2. Another cancer that is currently significant or needs ongoing treatment at the time of screening, they may not be eligible for the study
    3. Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.